Physician profile
Tuongvan Tran
NPI 1689667537
$9,025.31
in general payments reported to CMS, 2019-2025
57 companies · $1,242 in 2025
The $1,242 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,196 · 2020: $1,095 · 2021: $1,488 · 2022: $1,436 · 2023: $1,310 · 2024: $1,258 · 2025: $1,242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,795 · Education: $14.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,795.46 |
| Education | $14.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,192.30 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $1,047.01 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $997.75 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $738.85 | 2019-2025 | Spiriva Respimat, Jardiance, Stiolto Respimat |
| Pfizer INC. | $638.65 | 2019-2025 | |
| Lilly USA, LLC | $627.07 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $360.99 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Amgen INC. | $325.44 | 2019-2024 | Evenity, Prolia, Repatha |
| Janssen Pharmaceuticals, INC | $226.59 | 2019-2023 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $226.12 | 2021-2025 | Rexulti |
| Abbott Laboratories | $201.99 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Sanofi-Aventis U.S. LLC | $161.07 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $153.87 | 2019-2025 | Capvaxive, Vaxneuvance |
| Teva Pharmaceuticals USA, INC. | $148.56 | 2021-2024 | Ajovy |
| Biohaven Pharmaceutical Holding Company LTD. | $132.15 | 2022 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tuongvan Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.